Regulating the Dutch pharmaceutical market: Improving efficiency or controlling costs?

International Journal of Health Planning and Management

Volumn 20, Issue 4, 2005, Pages 351-374

  de Wolf, Peter ^a   Brouwer, Werner B F ^b   Rutten, Frans F H ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Cost containment; Drug pricing; Pharmaceuticals; Regulation; The Netherlands

Indexed keywords

GENERIC DRUG;

COST; INDUSTRIAL POLICY; PHARMACEUTICAL INDUSTRY; REGULATORY APPROACH;

ARTICLE; COMPETENCE; COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MEDICAL DECISION MAKING; NETHERLANDS; OUTPATIENT; PATIENT CARE; PHARMACIST; PHARMACY; PHYSICIAN ATTITUDE; PRESCRIPTION;

COST CONTROL; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; GOVERNMENT REGULATION; HEALTH EXPENDITURES; NETHERLANDS;

BENELUX; EURASIA; EUROPE; NETHERLANDS; WESTERN EUROPE;

EID: 28844466804     PISSN: 07496753     EISSN: None     Source Type: Journal    
DOI: 10.1002/hpm.819     Document Type: Article

References (21)

1. Boston Consulting Group. 2004. Bonussen en kortingen binnen de farmaceutische zorg in 2003 [Discounts and bonuses in pharmaceutical care in 2003]. BCG: The Hague.
2. Brouwer WBF, Rutten FFH. 2001. GVS geeft verkeerde signalen [Drug Reimbursement System gives wrong signal]. ESB 86: 884-886.
3. Brouwer WBF, Rutten FFH. 2002. Geef de dokter maar de schuld [Just blame it on the doctor]. Medisch Contact 57: 540-541.
4. Brouwer WBF, Schut FT. 1999. Priority care for employees: a blessing in disguise? Health Econ 8: 65-73.
5. Brouwer WBF, Hulst E, Rutten FFH. 2003. Generieke substitutie. [Generic substitution]. TSG, Tijdschrift voor Gezondheidswetenschappen 81(3): 162-165.
6. College voor Zorgverzekeringen (CVZ). 2003. GIPeilingen 1994-2002, December 2003, Diemen.
7. Commissie De Vries. 1999. Een helder recept [A clear prescription]. Ministerie van VWS: The Hague.
8. Delnoy DMJ, Ros CC, Groenewegen PP. 2001. Effecten van eigen bijdragen in het ziekenfonds in Nederland. [Effects of out-of-pocket payments for Dutch sickness fund insurants.] Tijdschrift voor Gezondheidswetenschappen 77(7): 406-412.
9. Habets PWM. 2003. Schijn en werkelijkheid. Winst van elektronisch voorschrijven is niet te meten [Fiction or real. Savings of electronic prescribing are not measurable]. Medisch Contact 58: 39.
10. Nefarma (Dutch Association of the Research-based Pharmaceutical Industry). 2002. Annual Report. Nefarma: The Hague.
11. Retail Wholesale Group. 1994. Onderzoek Farmaceutische Groothandel in de Extramurale markt. [Observation of the Dutch Pharmaceutical Wholesale Market.] RWG: De Meern.
12. Rutten FFH, Brouwer WBF. 2002. Meer zorg bij beperkt budget; een pleidooi voor een betere inzet van het doelmatigheidscriterium [More care with a limited budget; a plea for better use of the efficiency criterion]. Nederlands Tijdschrift voor de Geneeskunde 146(47): 2254-2258.
13. Rutten FFH, Brouwer WBF. 2003. De prijs van vraagsturing [The price of demand driven care]. In Zorgaanbod en cliëntenperspectief, RVZ (ed.). Raad voor de Volksgezondheid en Zorg (RVZ): Zoetermeer.
14. Schut FT, Brouwer WBF. 2004. De preferente apotheker? Jazeker. [The preferred pharmacist? Absolutely.] ESB 89: 266-269.
15. SFK (Foundation of Pharmaceutical Statistics). 1995. Data en Feiten [Facts and Figures]. SFK: The Hague.
16. SFK (Foundation of Pharmaceutical Statistics). 2001. Data en Feiten [Facts and Figures]. SFK: The Hague.
17. SFK (Foundation of Pharmaceutical Statistics), 2002. Data en Feiten [Facts and Figures]. SFK: The Hague.
18. SFK (Foundation of Pharmaceutical Statistics), 2003. Data en Feiten [Facts and Figures]. SFK: The Hague.
19. Westert G, Groenewegen PP. 1999. Regional disparities in health care supply in eleven European countries: does politics matter? Health Policy 47(2): 169-182.
20. Wolf P de. 1993. The pharmaceutical industry: towards one single market? In The Structure of European Industry, De Jong HW (ed.). Kluwer: Boston.
21. Wolters I, van Dijk L. 2002. Evaluatie Invoering Elektronisch Voorschrijf Systeem. [Evaluation of the Electronic Prescription System.] Nivel: Utrecht.